Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Information regarding a distinct drug named "perazine decanoate" is not readily available in scientific literature or common drug databases. Search results for "perazine decanoate" predominantly refer to either "perphenazine decanoate" or "fluphenazine decanoate", both of which are long-acting injectable antipsychotics belonging to the phenothiazine class. It is highly probable that "perazine decanoate" is a misnomer or a less common, potentially incorrect, reference to one of these established drugs. Therefore, a specific description for a standalone "perazine decanoate" cannot be provided. Perphenazine decanoate and fluphenazine decanoate are used in the management of schizophrenia and other psychotic disorders, acting primarily as dopamine D2 receptor antagonists.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on perazine decanoate.